Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors


Ozturk B., Coskun U., Sancak B., Yaman E., Buyukberber S., Benekli M.

INTERNATIONAL IMMUNOPHARMACOLOGY, vol.9, no.5, pp.645-648, 2009 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 9 Issue: 5
  • Publication Date: 2009
  • Doi Number: 10.1016/j.intimp.2009.02.004
  • Journal Name: INTERNATIONAL IMMUNOPHARMACOLOGY
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.645-648
  • Keywords: Head and neck tumor, Apoptosis, M30, M65, CASPASE-CLEAVED CYTOKERATIN-18, APOPTOSIS PROTEIN XIAP, X-LINKED INHIBITOR, CELL-DEATH, CIRCULATING BIOMARKERS, CLINICAL-EFFICACY, CANCER, REORGANIZATION, QUALIFICATION, VALIDATION

Abstract

Background: M30-Apoptosense and M65 ELISAs can detect caspase cleaved and intact forms of cytokeratin 18. As biologic marker of cell death, both assays can be useful to evaluate prognosis and chemotherapy response in the patients with breast, lung, and endometrium cancer. In the present study, we measured serum M30 and M65 levels in the patients with locally advanced head and neck tumors, and compared with healthy controls.